Taken together, InAc-NPs has the ability to maintain an effective memory immune response after an immune response, and is a potential mucosal inoculated intranasal agent for COVID-19 immunotherapy using TLR4 activator combined with adjuvant, which can inhibit the early invasion of SARS-CoV-2 infection. The gene discussed is TLR4; the disease is COVID-19.